A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2009-08-01

Summary

The objective of this 3-month study is to assess the safety and efficacy of EHT 0202 in addition to acetylcholinesterase inhibitor in patients suffering from Alzheimer's Disease.

• Phase: Phase 2

Details

• Lead Sponsor: Exonhit
• Treatments: Cholinesterase Inhibitors; Etazolate